drugset / Trial / NCT06264414

Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia

NCT06264414

Phase 3 Not yet recruiting 262 enrolled EMS
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the safety and efficacy of the DTT106 in the treatment of erectile dysfunction associated with benign prostatic hyperplasia

Timeline

Start
2025-02
Primary completion
2026-06
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Subject DTT106 Unknown Oral
Comparator Dutasteride Small molecule 0.5 mg Oral
Comparator Tamsulosin Other / unclassified 0.4 mg Oral